- Home
- ENSC vs KAVL Comparison
ENSC vs KAVL Comparison
Compare ENSC & KAVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- KAVL
- Stock Information
- Founded
- ENSC 2003
- KAVL 1998
- Country
- ENSC United States
- KAVL United States
- Employees
- ENSC N/A
- KAVL N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- KAVL Medicinal Chemicals and Botanical Products
- Sector
- ENSC Health Care
- KAVL Health Care
- Exchange
- ENSC Nasdaq
- KAVL Nasdaq
- Market Cap
- ENSC 5.2M
- KAVL 5.6M
- IPO Year
- ENSC N/A
- KAVL N/A
- Fundamental
- Price
- ENSC $2.15
- KAVL $0.66
- Analyst Decision
- ENSC
- KAVL
- Analyst Count
- ENSC 0
- KAVL 0
- Target Price
- ENSC N/A
- KAVL N/A
- AVG Volume (30 Days)
- ENSC 874.4K
- KAVL 6.3M
- Earning Date
- ENSC 08-13-2025
- KAVL 09-19-2025
- Dividend Yield
- ENSC N/A
- KAVL N/A
- EPS Growth
- ENSC N/A
- KAVL N/A
- EPS
- ENSC N/A
- KAVL N/A
- Revenue
- ENSC $6,224,081.00
- KAVL $1,698,426.00
- Revenue This Year
- ENSC N/A
- KAVL N/A
- Revenue Next Year
- ENSC $1,381.48
- KAVL N/A
- P/E Ratio
- ENSC N/A
- KAVL N/A
- Revenue Growth
- ENSC 256.35
- KAVL N/A
- 52 Week Low
- ENSC $1.62
- KAVL $0.45
- 52 Week High
- ENSC $14.67
- KAVL $1.95
- Technical
- Relative Strength Index (RSI)
- ENSC 49.40
- KAVL 63.48
- Support Level
- ENSC $1.99
- KAVL $0.51
- Resistance Level
- ENSC $2.25
- KAVL $0.80
- Average True Range (ATR)
- ENSC 0.17
- KAVL 0.07
- MACD
- ENSC -0.00
- KAVL 0.02
- Stochastic Oscillator
- ENSC 47.62
- KAVL 59.12
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.